ABOUT US
CONTACT US
FAQ
PRIVACY POLICY
REFUND AND CANCELLATION
BLOGS
COMPANIES
REPORTS
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Automative
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Global Oligonucleotide CDMO and CRDMO Services Market Research Report 2025
Published Date: March 2025
|
Report Code: QYRE-Auto-11M19332
Home | Market Reports | Business & Industrial| Pharmaceuticals & Biotech
Global Oligonucleotide CDMO and CRDMO Services Market Research Report 2025
BUY CHAPTERS

Global Oligonucleotide CDMO and CRDMO Services Market Research Report 2025

Code: QYRE-Auto-11M19332
Report
March 2025
Pages:98
QYResearch
Buy Now with 15% Discount
DESCRIPTION
TABLE OF CONTENT
TABLES & FIGURES
FEATURED COMPANIES
Companies
ST Pharm
EUROAPI
Danaher(IDT)
Merck
Eurofins Scientific
Thermo Fisher Scientific
Agilent Technologies
Nippon Shokubai
Eurogentec S.A
Ajinomoto Bio-Pharma
PeptiStar
Bachem
CordenPharma
Guangzhou RiboBio
Hongene Biotech
WuXi AppTec
Veliter
Ribobay Pharma
Chemexpress
Asymchem

Oligonucleotide CDMO and CRDMO Services Market Size

The global market for Oligonucleotide CDMO and CRDMO Services was valued at US$ 1536 million in the year 2024 and is projected to reach a revised size of US$ 2758 million by 2031, growing at a CAGR of 8.5% during the forecast period.

Oligonucleotide CDMO and CRDMO Services Market

Oligonucleotide CDMO and CRDMO Services Market

Oligonucleotide CDMO (Contract Development and Manufacturing Organization) and CRDMO (Contract Research, Development, and Manufacturing Organization) services provide end-to-end solutions for biopharmaceutical companies and research institutions, covering the entire process from R&D to commercial production. These services include process development, synthesis, purification, analytical method development, quality control, GMP manufacturing, and regulatory support. While CDMO primarily focuses on production and process optimization, CRDMO extends to early-stage research and preclinical development. With the rapid advancement of gene and RNA-based therapies, the demand for high-quality, regulatory-compliant oligonucleotide synthesis and manufacturing continues to grow, driving technological innovation and industrial capabilities in CDMO and CRDMO companies.
North American market for Oligonucleotide CDMO and CRDMO Services is estimated to increase from $ million in 2024 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Asia-Pacific market for Oligonucleotide CDMO and CRDMO Services is estimated to increase from $ million in 2024 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The global market for Oligonucleotide CDMO and CRDMO Services in Pharmaceuticals is estimated to increase from $ million in 2024 to $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The major global companies of Oligonucleotide CDMO and CRDMO Services include ST Pharm, EUROAPI, Danaher(IDT), Merck, Eurofins Scientific, Thermo Fisher Scientific, Agilent Technologies, Nippon Shokubai, Eurogentec, Ajinomoto Bio-Pharma, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.
This report aims to provide a comprehensive presentation of the global market for Oligonucleotide CDMO and CRDMO Services, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Oligonucleotide CDMO and CRDMO Services.
The Oligonucleotide CDMO and CRDMO Services market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Oligonucleotide CDMO and CRDMO Services market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Oligonucleotide CDMO and CRDMO Services companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation

Scope of Oligonucleotide CDMO and CRDMO Services Market Report

Report Metric Details
Report Name Oligonucleotide CDMO and CRDMO Services Market
Accounted market size in year US$ 1536 million
Forecasted market size in 2031 US$ 2758 million
CAGR 8.5%
Base Year year
Forecasted years 2025 - 2031
Segment by Type
  • Non-GMP Oligonucleotides
  • GMP Oligonucleotides
Segment by Application
  • Pharmaceuticals
  • Scientific Research
By Region
  • North America (United States, Canada)
  • Europe (Germany, France, UK, Italy, Russia) Rest of Europe
  • Nordic Countries
  • Asia-Pacific (China, Japan, South Korea)
  • Southeast Asia (India, Australia)
  • Rest of Asia
  • Latin America (Mexico, Brazil)
  • Rest of Latin America
  • Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company ST Pharm, EUROAPI, Danaher(IDT), Merck, Eurofins Scientific, Thermo Fisher Scientific, Agilent Technologies, Nippon Shokubai, Eurogentec, Ajinomoto Bio-Pharma, PeptiStar, Bachem, CordenPharma, Guangzhou RiboBio, Hongene Biotech, WuXi AppTec, Veliter, Ribobay Pharma, ChemExpress, Asymchem
Forecast units USD million in value
Report coverage Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

  • Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
  • Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
  • Chapter 3: Detailed analysis of Oligonucleotide CDMO and CRDMO Services company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
  • Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
  • Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
  • Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
  • Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
  • Chapter 12: The main points and conclusions of the report.

FAQ for this report

How fast is Oligonucleotide CDMO and CRDMO Services Market growing?

Ans: The Oligonucleotide CDMO and CRDMO Services Market witnessing a CAGR of 8.5% during the forecast period 2025-2031.

What is the Oligonucleotide CDMO and CRDMO Services Market size in 2031?

Ans: The Oligonucleotide CDMO and CRDMO Services Market size in 2031 will be US$ 2758 million.

Who are the main players in the Oligonucleotide CDMO and CRDMO Services Market report?

Ans: The main players in the Oligonucleotide CDMO and CRDMO Services Market are ST Pharm, EUROAPI, Danaher(IDT), Merck, Eurofins Scientific, Thermo Fisher Scientific, Agilent Technologies, Nippon Shokubai, Eurogentec, Ajinomoto Bio-Pharma, PeptiStar, Bachem, CordenPharma, Guangzhou RiboBio, Hongene Biotech, WuXi AppTec, Veliter, Ribobay Pharma, ChemExpress, Asymchem

What are the Application segmentation covered in the Oligonucleotide CDMO and CRDMO Services Market report?

Ans: The Applications covered in the Oligonucleotide CDMO and CRDMO Services Market report are Pharmaceuticals, Scientific Research

What are the Type segmentation covered in the Oligonucleotide CDMO and CRDMO Services Market report?

Ans: The Types covered in the Oligonucleotide CDMO and CRDMO Services Market report are Non-GMP Oligonucleotides, GMP Oligonucleotides

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Oligonucleotide CDMO and CRDMO Services Market Size Growth Rate by Type: 2020 VS 2024 VS 2031
1.2.2 Non-GMP Oligonucleotides
1.2.3 GMP Oligonucleotides
1.3 Market by Application
1.3.1 Global Oligonucleotide CDMO and CRDMO Services Market Growth by Application: 2020 VS 2024 VS 2031
1.3.2 Pharmaceuticals
1.3.3 Scientific Research
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Oligonucleotide CDMO and CRDMO Services Market Perspective (2020-2031)
2.2 Global Oligonucleotide CDMO and CRDMO Services Growth Trends by Region
2.2.1 Global Oligonucleotide CDMO and CRDMO Services Market Size by Region: 2020 VS 2024 VS 2031
2.2.2 Oligonucleotide CDMO and CRDMO Services Historic Market Size by Region (2020-2025)
2.2.3 Oligonucleotide CDMO and CRDMO Services Forecasted Market Size by Region (2026-2031)
2.3 Oligonucleotide CDMO and CRDMO Services Market Dynamics
2.3.1 Oligonucleotide CDMO and CRDMO Services Industry Trends
2.3.2 Oligonucleotide CDMO and CRDMO Services Market Drivers
2.3.3 Oligonucleotide CDMO and CRDMO Services Market Challenges
2.3.4 Oligonucleotide CDMO and CRDMO Services Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Oligonucleotide CDMO and CRDMO Services Players by Revenue
3.1.1 Global Top Oligonucleotide CDMO and CRDMO Services Players by Revenue (2020-2025)
3.1.2 Global Oligonucleotide CDMO and CRDMO Services Revenue Market Share by Players (2020-2025)
3.2 Global Top Oligonucleotide CDMO and CRDMO Services Players by Company Type and Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players Ranking by Oligonucleotide CDMO and CRDMO Services Revenue
3.4 Global Oligonucleotide CDMO and CRDMO Services Market Concentration Ratio
3.4.1 Global Oligonucleotide CDMO and CRDMO Services Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Oligonucleotide CDMO and CRDMO Services Revenue in 2024
3.5 Global Key Players of Oligonucleotide CDMO and CRDMO Services Head office and Area Served
3.6 Global Key Players of Oligonucleotide CDMO and CRDMO Services, Product and Application
3.7 Global Key Players of Oligonucleotide CDMO and CRDMO Services, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 Oligonucleotide CDMO and CRDMO Services Breakdown Data by Type
4.1 Global Oligonucleotide CDMO and CRDMO Services Historic Market Size by Type (2020-2025)
4.2 Global Oligonucleotide CDMO and CRDMO Services Forecasted Market Size by Type (2026-2031)
5 Oligonucleotide CDMO and CRDMO Services Breakdown Data by Application
5.1 Global Oligonucleotide CDMO and CRDMO Services Historic Market Size by Application (2020-2025)
5.2 Global Oligonucleotide CDMO and CRDMO Services Forecasted Market Size by Application (2026-2031)
6 North America
6.1 North America Oligonucleotide CDMO and CRDMO Services Market Size (2020-2031)
6.2 North America Oligonucleotide CDMO and CRDMO Services Market Growth Rate by Country: 2020 VS 2024 VS 2031
6.3 North America Oligonucleotide CDMO and CRDMO Services Market Size by Country (2020-2025)
6.4 North America Oligonucleotide CDMO and CRDMO Services Market Size by Country (2026-2031)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Oligonucleotide CDMO and CRDMO Services Market Size (2020-2031)
7.2 Europe Oligonucleotide CDMO and CRDMO Services Market Growth Rate by Country: 2020 VS 2024 VS 2031
7.3 Europe Oligonucleotide CDMO and CRDMO Services Market Size by Country (2020-2025)
7.4 Europe Oligonucleotide CDMO and CRDMO Services Market Size by Country (2026-2031)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Oligonucleotide CDMO and CRDMO Services Market Size (2020-2031)
8.2 Asia-Pacific Oligonucleotide CDMO and CRDMO Services Market Growth Rate by Region: 2020 VS 2024 VS 2031
8.3 Asia-Pacific Oligonucleotide CDMO and CRDMO Services Market Size by Region (2020-2025)
8.4 Asia-Pacific Oligonucleotide CDMO and CRDMO Services Market Size by Region (2026-2031)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Oligonucleotide CDMO and CRDMO Services Market Size (2020-2031)
9.2 Latin America Oligonucleotide CDMO and CRDMO Services Market Growth Rate by Country: 2020 VS 2024 VS 2031
9.3 Latin America Oligonucleotide CDMO and CRDMO Services Market Size by Country (2020-2025)
9.4 Latin America Oligonucleotide CDMO and CRDMO Services Market Size by Country (2026-2031)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Oligonucleotide CDMO and CRDMO Services Market Size (2020-2031)
10.2 Middle East & Africa Oligonucleotide CDMO and CRDMO Services Market Growth Rate by Country: 2020 VS 2024 VS 2031
10.3 Middle East & Africa Oligonucleotide CDMO and CRDMO Services Market Size by Country (2020-2025)
10.4 Middle East & Africa Oligonucleotide CDMO and CRDMO Services Market Size by Country (2026-2031)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 ST Pharm
11.1.1 ST Pharm Company Details
11.1.2 ST Pharm Business Overview
11.1.3 ST Pharm Oligonucleotide CDMO and CRDMO Services Introduction
11.1.4 ST Pharm Revenue in Oligonucleotide CDMO and CRDMO Services Business (2020-2025)
11.1.5 ST Pharm Recent Development
11.2 EUROAPI
11.2.1 EUROAPI Company Details
11.2.2 EUROAPI Business Overview
11.2.3 EUROAPI Oligonucleotide CDMO and CRDMO Services Introduction
11.2.4 EUROAPI Revenue in Oligonucleotide CDMO and CRDMO Services Business (2020-2025)
11.2.5 EUROAPI Recent Development
11.3 Danaher(IDT)
11.3.1 Danaher(IDT) Company Details
11.3.2 Danaher(IDT) Business Overview
11.3.3 Danaher(IDT) Oligonucleotide CDMO and CRDMO Services Introduction
11.3.4 Danaher(IDT) Revenue in Oligonucleotide CDMO and CRDMO Services Business (2020-2025)
11.3.5 Danaher(IDT) Recent Development
11.4 Merck
11.4.1 Merck Company Details
11.4.2 Merck Business Overview
11.4.3 Merck Oligonucleotide CDMO and CRDMO Services Introduction
11.4.4 Merck Revenue in Oligonucleotide CDMO and CRDMO Services Business (2020-2025)
11.4.5 Merck Recent Development
11.5 Eurofins Scientific
11.5.1 Eurofins Scientific Company Details
11.5.2 Eurofins Scientific Business Overview
11.5.3 Eurofins Scientific Oligonucleotide CDMO and CRDMO Services Introduction
11.5.4 Eurofins Scientific Revenue in Oligonucleotide CDMO and CRDMO Services Business (2020-2025)
11.5.5 Eurofins Scientific Recent Development
11.6 Thermo Fisher Scientific
11.6.1 Thermo Fisher Scientific Company Details
11.6.2 Thermo Fisher Scientific Business Overview
11.6.3 Thermo Fisher Scientific Oligonucleotide CDMO and CRDMO Services Introduction
11.6.4 Thermo Fisher Scientific Revenue in Oligonucleotide CDMO and CRDMO Services Business (2020-2025)
11.6.5 Thermo Fisher Scientific Recent Development
11.7 Agilent Technologies
11.7.1 Agilent Technologies Company Details
11.7.2 Agilent Technologies Business Overview
11.7.3 Agilent Technologies Oligonucleotide CDMO and CRDMO Services Introduction
11.7.4 Agilent Technologies Revenue in Oligonucleotide CDMO and CRDMO Services Business (2020-2025)
11.7.5 Agilent Technologies Recent Development
11.8 Nippon Shokubai
11.8.1 Nippon Shokubai Company Details
11.8.2 Nippon Shokubai Business Overview
11.8.3 Nippon Shokubai Oligonucleotide CDMO and CRDMO Services Introduction
11.8.4 Nippon Shokubai Revenue in Oligonucleotide CDMO and CRDMO Services Business (2020-2025)
11.8.5 Nippon Shokubai Recent Development
11.9 Eurogentec
11.9.1 Eurogentec Company Details
11.9.2 Eurogentec Business Overview
11.9.3 Eurogentec Oligonucleotide CDMO and CRDMO Services Introduction
11.9.4 Eurogentec Revenue in Oligonucleotide CDMO and CRDMO Services Business (2020-2025)
11.9.5 Eurogentec Recent Development
11.10 Ajinomoto Bio-Pharma
11.10.1 Ajinomoto Bio-Pharma Company Details
11.10.2 Ajinomoto Bio-Pharma Business Overview
11.10.3 Ajinomoto Bio-Pharma Oligonucleotide CDMO and CRDMO Services Introduction
11.10.4 Ajinomoto Bio-Pharma Revenue in Oligonucleotide CDMO and CRDMO Services Business (2020-2025)
11.10.5 Ajinomoto Bio-Pharma Recent Development
11.11 PeptiStar
11.11.1 PeptiStar Company Details
11.11.2 PeptiStar Business Overview
11.11.3 PeptiStar Oligonucleotide CDMO and CRDMO Services Introduction
11.11.4 PeptiStar Revenue in Oligonucleotide CDMO and CRDMO Services Business (2020-2025)
11.11.5 PeptiStar Recent Development
11.12 Bachem
11.12.1 Bachem Company Details
11.12.2 Bachem Business Overview
11.12.3 Bachem Oligonucleotide CDMO and CRDMO Services Introduction
11.12.4 Bachem Revenue in Oligonucleotide CDMO and CRDMO Services Business (2020-2025)
11.12.5 Bachem Recent Development
11.13 CordenPharma
11.13.1 CordenPharma Company Details
11.13.2 CordenPharma Business Overview
11.13.3 CordenPharma Oligonucleotide CDMO and CRDMO Services Introduction
11.13.4 CordenPharma Revenue in Oligonucleotide CDMO and CRDMO Services Business (2020-2025)
11.13.5 CordenPharma Recent Development
11.14 Guangzhou RiboBio
11.14.1 Guangzhou RiboBio Company Details
11.14.2 Guangzhou RiboBio Business Overview
11.14.3 Guangzhou RiboBio Oligonucleotide CDMO and CRDMO Services Introduction
11.14.4 Guangzhou RiboBio Revenue in Oligonucleotide CDMO and CRDMO Services Business (2020-2025)
11.14.5 Guangzhou RiboBio Recent Development
11.15 Hongene Biotech
11.15.1 Hongene Biotech Company Details
11.15.2 Hongene Biotech Business Overview
11.15.3 Hongene Biotech Oligonucleotide CDMO and CRDMO Services Introduction
11.15.4 Hongene Biotech Revenue in Oligonucleotide CDMO and CRDMO Services Business (2020-2025)
11.15.5 Hongene Biotech Recent Development
11.16 WuXi AppTec
11.16.1 WuXi AppTec Company Details
11.16.2 WuXi AppTec Business Overview
11.16.3 WuXi AppTec Oligonucleotide CDMO and CRDMO Services Introduction
11.16.4 WuXi AppTec Revenue in Oligonucleotide CDMO and CRDMO Services Business (2020-2025)
11.16.5 WuXi AppTec Recent Development
11.17 Veliter
11.17.1 Veliter Company Details
11.17.2 Veliter Business Overview
11.17.3 Veliter Oligonucleotide CDMO and CRDMO Services Introduction
11.17.4 Veliter Revenue in Oligonucleotide CDMO and CRDMO Services Business (2020-2025)
11.17.5 Veliter Recent Development
11.18 Ribobay Pharma
11.18.1 Ribobay Pharma Company Details
11.18.2 Ribobay Pharma Business Overview
11.18.3 Ribobay Pharma Oligonucleotide CDMO and CRDMO Services Introduction
11.18.4 Ribobay Pharma Revenue in Oligonucleotide CDMO and CRDMO Services Business (2020-2025)
11.18.5 Ribobay Pharma Recent Development
11.19 ChemExpress
11.19.1 ChemExpress Company Details
11.19.2 ChemExpress Business Overview
11.19.3 ChemExpress Oligonucleotide CDMO and CRDMO Services Introduction
11.19.4 ChemExpress Revenue in Oligonucleotide CDMO and CRDMO Services Business (2020-2025)
11.19.5 ChemExpress Recent Development
11.20 Asymchem
11.20.1 Asymchem Company Details
11.20.2 Asymchem Business Overview
11.20.3 Asymchem Oligonucleotide CDMO and CRDMO Services Introduction
11.20.4 Asymchem Revenue in Oligonucleotide CDMO and CRDMO Services Business (2020-2025)
11.20.5 Asymchem Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.1.1 Research Programs/Design
13.1.1.2 Market Size Estimation
13.1.1.3 Market Breakdown and Data Triangulation
13.1.2 Data Source
13.1.2.1 Secondary Sources
13.1.2.2 Primary Sources
13.2 Author Details
13.3 Disclaimer
FEATURED COMPANIES
Companies
ST Pharm
EUROAPI
Danaher(IDT)
Merck
Eurofins Scientific
Thermo Fisher Scientific
Agilent Technologies
Nippon Shokubai
Eurogentec S.A
Ajinomoto Bio-Pharma
PeptiStar
Bachem
CordenPharma
Guangzhou RiboBio
Hongene Biotech
WuXi AppTec
Veliter
Ribobay Pharma
Chemexpress
Asymchem
List of Tables
 Table 1. Global Oligonucleotide CDMO and CRDMO Services Market Size Growth Rate by Type (US$ Million): 2020 VS 2024 VS 2031
 Table 2. Key Players of Non-GMP Oligonucleotides
 Table 3. Key Players of GMP Oligonucleotides
 Table 4. Global Oligonucleotide CDMO and CRDMO Services Market Size Growth by Application (US$ Million): 2020 VS 2024 VS 2031
 Table 5. Global Oligonucleotide CDMO and CRDMO Services Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
 Table 6. Global Oligonucleotide CDMO and CRDMO Services Market Size by Region (2020-2025) & (US$ Million)
 Table 7. Global Oligonucleotide CDMO and CRDMO Services Market Share by Region (2020-2025)
 Table 8. Global Oligonucleotide CDMO and CRDMO Services Forecasted Market Size by Region (2026-2031) & (US$ Million)
 Table 9. Global Oligonucleotide CDMO and CRDMO Services Market Share by Region (2026-2031)
 Table 10. Oligonucleotide CDMO and CRDMO Services Market Trends
 Table 11. Oligonucleotide CDMO and CRDMO Services Market Drivers
 Table 12. Oligonucleotide CDMO and CRDMO Services Market Challenges
 Table 13. Oligonucleotide CDMO and CRDMO Services Market Restraints
 Table 14. Global Oligonucleotide CDMO and CRDMO Services Revenue by Players (2020-2025) & (US$ Million)
 Table 15. Global Oligonucleotide CDMO and CRDMO Services Market Share by Players (2020-2025)
 Table 16. Global Top Oligonucleotide CDMO and CRDMO Services Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Oligonucleotide CDMO and CRDMO Services as of 2024)
 Table 17. Ranking of Global Top Oligonucleotide CDMO and CRDMO Services Companies by Revenue (US$ Million) in 2024
 Table 18. Global 5 Largest Players Market Share by Oligonucleotide CDMO and CRDMO Services Revenue (CR5 and HHI) & (2020-2025)
 Table 19. Global Key Players of Oligonucleotide CDMO and CRDMO Services, Headquarters and Area Served
 Table 20. Global Key Players of Oligonucleotide CDMO and CRDMO Services, Product and Application
 Table 21. Global Key Players of Oligonucleotide CDMO and CRDMO Services, Date of Enter into This Industry
 Table 22. Mergers & Acquisitions, Expansion Plans
 Table 23. Global Oligonucleotide CDMO and CRDMO Services Market Size by Type (2020-2025) & (US$ Million)
 Table 24. Global Oligonucleotide CDMO and CRDMO Services Revenue Market Share by Type (2020-2025)
 Table 25. Global Oligonucleotide CDMO and CRDMO Services Forecasted Market Size by Type (2026-2031) & (US$ Million)
 Table 26. Global Oligonucleotide CDMO and CRDMO Services Revenue Market Share by Type (2026-2031)
 Table 27. Global Oligonucleotide CDMO and CRDMO Services Market Size by Application (2020-2025) & (US$ Million)
 Table 28. Global Oligonucleotide CDMO and CRDMO Services Revenue Market Share by Application (2020-2025)
 Table 29. Global Oligonucleotide CDMO and CRDMO Services Forecasted Market Size by Application (2026-2031) & (US$ Million)
 Table 30. Global Oligonucleotide CDMO and CRDMO Services Revenue Market Share by Application (2026-2031)
 Table 31. North America Oligonucleotide CDMO and CRDMO Services Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
 Table 32. North America Oligonucleotide CDMO and CRDMO Services Market Size by Country (2020-2025) & (US$ Million)
 Table 33. North America Oligonucleotide CDMO and CRDMO Services Market Size by Country (2026-2031) & (US$ Million)
 Table 34. Europe Oligonucleotide CDMO and CRDMO Services Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
 Table 35. Europe Oligonucleotide CDMO and CRDMO Services Market Size by Country (2020-2025) & (US$ Million)
 Table 36. Europe Oligonucleotide CDMO and CRDMO Services Market Size by Country (2026-2031) & (US$ Million)
 Table 37. Asia-Pacific Oligonucleotide CDMO and CRDMO Services Market Size Growth Rate by Region (US$ Million): 2020 VS 2024 VS 2031
 Table 38. Asia-Pacific Oligonucleotide CDMO and CRDMO Services Market Size by Region (2020-2025) & (US$ Million)
 Table 39. Asia-Pacific Oligonucleotide CDMO and CRDMO Services Market Size by Region (2026-2031) & (US$ Million)
 Table 40. Latin America Oligonucleotide CDMO and CRDMO Services Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
 Table 41. Latin America Oligonucleotide CDMO and CRDMO Services Market Size by Country (2020-2025) & (US$ Million)
 Table 42. Latin America Oligonucleotide CDMO and CRDMO Services Market Size by Country (2026-2031) & (US$ Million)
 Table 43. Middle East & Africa Oligonucleotide CDMO and CRDMO Services Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
 Table 44. Middle East & Africa Oligonucleotide CDMO and CRDMO Services Market Size by Country (2020-2025) & (US$ Million)
 Table 45. Middle East & Africa Oligonucleotide CDMO and CRDMO Services Market Size by Country (2026-2031) & (US$ Million)
 Table 46. ST Pharm Company Details
 Table 47. ST Pharm Business Overview
 Table 48. ST Pharm Oligonucleotide CDMO and CRDMO Services Product
 Table 49. ST Pharm Revenue in Oligonucleotide CDMO and CRDMO Services Business (2020-2025) & (US$ Million)
 Table 50. ST Pharm Recent Development
 Table 51. EUROAPI Company Details
 Table 52. EUROAPI Business Overview
 Table 53. EUROAPI Oligonucleotide CDMO and CRDMO Services Product
 Table 54. EUROAPI Revenue in Oligonucleotide CDMO and CRDMO Services Business (2020-2025) & (US$ Million)
 Table 55. EUROAPI Recent Development
 Table 56. Danaher(IDT) Company Details
 Table 57. Danaher(IDT) Business Overview
 Table 58. Danaher(IDT) Oligonucleotide CDMO and CRDMO Services Product
 Table 59. Danaher(IDT) Revenue in Oligonucleotide CDMO and CRDMO Services Business (2020-2025) & (US$ Million)
 Table 60. Danaher(IDT) Recent Development
 Table 61. Merck Company Details
 Table 62. Merck Business Overview
 Table 63. Merck Oligonucleotide CDMO and CRDMO Services Product
 Table 64. Merck Revenue in Oligonucleotide CDMO and CRDMO Services Business (2020-2025) & (US$ Million)
 Table 65. Merck Recent Development
 Table 66. Eurofins Scientific Company Details
 Table 67. Eurofins Scientific Business Overview
 Table 68. Eurofins Scientific Oligonucleotide CDMO and CRDMO Services Product
 Table 69. Eurofins Scientific Revenue in Oligonucleotide CDMO and CRDMO Services Business (2020-2025) & (US$ Million)
 Table 70. Eurofins Scientific Recent Development
 Table 71. Thermo Fisher Scientific Company Details
 Table 72. Thermo Fisher Scientific Business Overview
 Table 73. Thermo Fisher Scientific Oligonucleotide CDMO and CRDMO Services Product
 Table 74. Thermo Fisher Scientific Revenue in Oligonucleotide CDMO and CRDMO Services Business (2020-2025) & (US$ Million)
 Table 75. Thermo Fisher Scientific Recent Development
 Table 76. Agilent Technologies Company Details
 Table 77. Agilent Technologies Business Overview
 Table 78. Agilent Technologies Oligonucleotide CDMO and CRDMO Services Product
 Table 79. Agilent Technologies Revenue in Oligonucleotide CDMO and CRDMO Services Business (2020-2025) & (US$ Million)
 Table 80. Agilent Technologies Recent Development
 Table 81. Nippon Shokubai Company Details
 Table 82. Nippon Shokubai Business Overview
 Table 83. Nippon Shokubai Oligonucleotide CDMO and CRDMO Services Product
 Table 84. Nippon Shokubai Revenue in Oligonucleotide CDMO and CRDMO Services Business (2020-2025) & (US$ Million)
 Table 85. Nippon Shokubai Recent Development
 Table 86. Eurogentec Company Details
 Table 87. Eurogentec Business Overview
 Table 88. Eurogentec Oligonucleotide CDMO and CRDMO Services Product
 Table 89. Eurogentec Revenue in Oligonucleotide CDMO and CRDMO Services Business (2020-2025) & (US$ Million)
 Table 90. Eurogentec Recent Development
 Table 91. Ajinomoto Bio-Pharma Company Details
 Table 92. Ajinomoto Bio-Pharma Business Overview
 Table 93. Ajinomoto Bio-Pharma Oligonucleotide CDMO and CRDMO Services Product
 Table 94. Ajinomoto Bio-Pharma Revenue in Oligonucleotide CDMO and CRDMO Services Business (2020-2025) & (US$ Million)
 Table 95. Ajinomoto Bio-Pharma Recent Development
 Table 96. PeptiStar Company Details
 Table 97. PeptiStar Business Overview
 Table 98. PeptiStar Oligonucleotide CDMO and CRDMO Services Product
 Table 99. PeptiStar Revenue in Oligonucleotide CDMO and CRDMO Services Business (2020-2025) & (US$ Million)
 Table 100. PeptiStar Recent Development
 Table 101. Bachem Company Details
 Table 102. Bachem Business Overview
 Table 103. Bachem Oligonucleotide CDMO and CRDMO Services Product
 Table 104. Bachem Revenue in Oligonucleotide CDMO and CRDMO Services Business (2020-2025) & (US$ Million)
 Table 105. Bachem Recent Development
 Table 106. CordenPharma Company Details
 Table 107. CordenPharma Business Overview
 Table 108. CordenPharma Oligonucleotide CDMO and CRDMO Services Product
 Table 109. CordenPharma Revenue in Oligonucleotide CDMO and CRDMO Services Business (2020-2025) & (US$ Million)
 Table 110. CordenPharma Recent Development
 Table 111. Guangzhou RiboBio Company Details
 Table 112. Guangzhou RiboBio Business Overview
 Table 113. Guangzhou RiboBio Oligonucleotide CDMO and CRDMO Services Product
 Table 114. Guangzhou RiboBio Revenue in Oligonucleotide CDMO and CRDMO Services Business (2020-2025) & (US$ Million)
 Table 115. Guangzhou RiboBio Recent Development
 Table 116. Hongene Biotech Company Details
 Table 117. Hongene Biotech Business Overview
 Table 118. Hongene Biotech Oligonucleotide CDMO and CRDMO Services Product
 Table 119. Hongene Biotech Revenue in Oligonucleotide CDMO and CRDMO Services Business (2020-2025) & (US$ Million)
 Table 120. Hongene Biotech Recent Development
 Table 121. WuXi AppTec Company Details
 Table 122. WuXi AppTec Business Overview
 Table 123. WuXi AppTec Oligonucleotide CDMO and CRDMO Services Product
 Table 124. WuXi AppTec Revenue in Oligonucleotide CDMO and CRDMO Services Business (2020-2025) & (US$ Million)
 Table 125. WuXi AppTec Recent Development
 Table 126. Veliter Company Details
 Table 127. Veliter Business Overview
 Table 128. Veliter Oligonucleotide CDMO and CRDMO Services Product
 Table 129. Veliter Revenue in Oligonucleotide CDMO and CRDMO Services Business (2020-2025) & (US$ Million)
 Table 130. Veliter Recent Development
 Table 131. Ribobay Pharma Company Details
 Table 132. Ribobay Pharma Business Overview
 Table 133. Ribobay Pharma Oligonucleotide CDMO and CRDMO Services Product
 Table 134. Ribobay Pharma Revenue in Oligonucleotide CDMO and CRDMO Services Business (2020-2025) & (US$ Million)
 Table 135. Ribobay Pharma Recent Development
 Table 136. ChemExpress Company Details
 Table 137. ChemExpress Business Overview
 Table 138. ChemExpress Oligonucleotide CDMO and CRDMO Services Product
 Table 139. ChemExpress Revenue in Oligonucleotide CDMO and CRDMO Services Business (2020-2025) & (US$ Million)
 Table 140. ChemExpress Recent Development
 Table 141. Asymchem Company Details
 Table 142. Asymchem Business Overview
 Table 143. Asymchem Oligonucleotide CDMO and CRDMO Services Product
 Table 144. Asymchem Revenue in Oligonucleotide CDMO and CRDMO Services Business (2020-2025) & (US$ Million)
 Table 145. Asymchem Recent Development
 Table 146. Research Programs/Design for This Report
 Table 147. Key Data Information from Secondary Sources
 Table 148. Key Data Information from Primary Sources
 Table 149. Authors List of This Report


List of Figures
 Figure 1. Oligonucleotide CDMO and CRDMO Services Picture
 Figure 2. Global Oligonucleotide CDMO and CRDMO Services Market Size Comparison by Type (2020-2031) & (US$ Million)
 Figure 3. Global Oligonucleotide CDMO and CRDMO Services Market Share by Type: 2024 VS 2031
 Figure 4. Non-GMP Oligonucleotides Features
 Figure 5. GMP Oligonucleotides Features
 Figure 6. Global Oligonucleotide CDMO and CRDMO Services Market Size by Application (2020-2031) & (US$ Million)
 Figure 7. Global Oligonucleotide CDMO and CRDMO Services Market Share by Application: 2024 VS 2031
 Figure 8. Pharmaceuticals Case Studies
 Figure 9. Scientific Research Case Studies
 Figure 10. Oligonucleotide CDMO and CRDMO Services Report Years Considered
 Figure 11. Global Oligonucleotide CDMO and CRDMO Services Market Size (US$ Million), Year-over-Year: 2020-2031
 Figure 12. Global Oligonucleotide CDMO and CRDMO Services Market Size, (US$ Million), 2020 VS 2024 VS 2031
 Figure 13. Global Oligonucleotide CDMO and CRDMO Services Market Share by Region: 2024 VS 2031
 Figure 14. Global Oligonucleotide CDMO and CRDMO Services Market Share by Players in 2024
 Figure 15. Global Oligonucleotide CDMO and CRDMO Services Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
 Figure 16. The Top 10 and 5 Players Market Share by Oligonucleotide CDMO and CRDMO Services Revenue in 2024
 Figure 17. North America Oligonucleotide CDMO and CRDMO Services Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 18. North America Oligonucleotide CDMO and CRDMO Services Market Share by Country (2020-2031)
 Figure 19. United States Oligonucleotide CDMO and CRDMO Services Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 20. Canada Oligonucleotide CDMO and CRDMO Services Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 21. Europe Oligonucleotide CDMO and CRDMO Services Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 22. Europe Oligonucleotide CDMO and CRDMO Services Market Share by Country (2020-2031)
 Figure 23. Germany Oligonucleotide CDMO and CRDMO Services Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 24. France Oligonucleotide CDMO and CRDMO Services Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 25. U.K. Oligonucleotide CDMO and CRDMO Services Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 26. Italy Oligonucleotide CDMO and CRDMO Services Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 27. Russia Oligonucleotide CDMO and CRDMO Services Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 28. Nordic Countries Oligonucleotide CDMO and CRDMO Services Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 29. Asia-Pacific Oligonucleotide CDMO and CRDMO Services Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 30. Asia-Pacific Oligonucleotide CDMO and CRDMO Services Market Share by Region (2020-2031)
 Figure 31. China Oligonucleotide CDMO and CRDMO Services Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 32. Japan Oligonucleotide CDMO and CRDMO Services Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 33. South Korea Oligonucleotide CDMO and CRDMO Services Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 34. Southeast Asia Oligonucleotide CDMO and CRDMO Services Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 35. India Oligonucleotide CDMO and CRDMO Services Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 36. Australia Oligonucleotide CDMO and CRDMO Services Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 37. Latin America Oligonucleotide CDMO and CRDMO Services Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 38. Latin America Oligonucleotide CDMO and CRDMO Services Market Share by Country (2020-2031)
 Figure 39. Mexico Oligonucleotide CDMO and CRDMO Services Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 40. Brazil Oligonucleotide CDMO and CRDMO Services Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 41. Middle East & Africa Oligonucleotide CDMO and CRDMO Services Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 42. Middle East & Africa Oligonucleotide CDMO and CRDMO Services Market Share by Country (2020-2031)
 Figure 43. Turkey Oligonucleotide CDMO and CRDMO Services Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 44. Saudi Arabia Oligonucleotide CDMO and CRDMO Services Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 45. UAE Oligonucleotide CDMO and CRDMO Services Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 46. ST Pharm Revenue Growth Rate in Oligonucleotide CDMO and CRDMO Services Business (2020-2025)
 Figure 47. EUROAPI Revenue Growth Rate in Oligonucleotide CDMO and CRDMO Services Business (2020-2025)
 Figure 48. Danaher(IDT) Revenue Growth Rate in Oligonucleotide CDMO and CRDMO Services Business (2020-2025)
 Figure 49. Merck Revenue Growth Rate in Oligonucleotide CDMO and CRDMO Services Business (2020-2025)
 Figure 50. Eurofins Scientific Revenue Growth Rate in Oligonucleotide CDMO and CRDMO Services Business (2020-2025)
 Figure 51. Thermo Fisher Scientific Revenue Growth Rate in Oligonucleotide CDMO and CRDMO Services Business (2020-2025)
 Figure 52. Agilent Technologies Revenue Growth Rate in Oligonucleotide CDMO and CRDMO Services Business (2020-2025)
 Figure 53. Nippon Shokubai Revenue Growth Rate in Oligonucleotide CDMO and CRDMO Services Business (2020-2025)
 Figure 54. Eurogentec Revenue Growth Rate in Oligonucleotide CDMO and CRDMO Services Business (2020-2025)
 Figure 55. Ajinomoto Bio-Pharma Revenue Growth Rate in Oligonucleotide CDMO and CRDMO Services Business (2020-2025)
 Figure 56. PeptiStar Revenue Growth Rate in Oligonucleotide CDMO and CRDMO Services Business (2020-2025)
 Figure 57. Bachem Revenue Growth Rate in Oligonucleotide CDMO and CRDMO Services Business (2020-2025)
 Figure 58. CordenPharma Revenue Growth Rate in Oligonucleotide CDMO and CRDMO Services Business (2020-2025)
 Figure 59. Guangzhou RiboBio Revenue Growth Rate in Oligonucleotide CDMO and CRDMO Services Business (2020-2025)
 Figure 60. Hongene Biotech Revenue Growth Rate in Oligonucleotide CDMO and CRDMO Services Business (2020-2025)
 Figure 61. WuXi AppTec Revenue Growth Rate in Oligonucleotide CDMO and CRDMO Services Business (2020-2025)
 Figure 62. Veliter Revenue Growth Rate in Oligonucleotide CDMO and CRDMO Services Business (2020-2025)
 Figure 63. Ribobay Pharma Revenue Growth Rate in Oligonucleotide CDMO and CRDMO Services Business (2020-2025)
 Figure 64. ChemExpress Revenue Growth Rate in Oligonucleotide CDMO and CRDMO Services Business (2020-2025)
 Figure 65. Asymchem Revenue Growth Rate in Oligonucleotide CDMO and CRDMO Services Business (2020-2025)
 Figure 66. Bottom-up and Top-down Approaches for This Report
 Figure 67. Data Triangulation
 Figure 68. Key Executives Interviewed
SELECT A FORMAT
Added to Cart
Electronic (PDF)

$2900

This license allows only one user to access the PDF.
Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together
Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report
Add to Cart
Buy Now (15% Discount)
INQUIRE FOR DISCOUNT

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

Novocure

SIMILAR REPORTS

Global Oligonucleotide Drug CDMO Services Market Research Report 2024
Global Oligonucleotide CDMO Market Research Report 2025
Global Cell and Gene Therapy CDMO Services Market Research Report 2024
Global mRNA CDMO Service Market Research Report 2024
Global Plasmid DNA CDMO Service Market Research Report 2024
CGT CDMO Market
Global Full Service CDMO Market Research Report 2024
Global Peptide Synthesis CDMO Services Market Research Report 2024
Global Viral Vector Manufacturing CDMO Services Market Research Report 2024
Global Chemical CDMO Market Research Report 2024
Global Aptamer CDMO Market Research Report 2024
Global Pharmaceutical Contract Development and Manufacturing Organization Market Research Report 2025
Global Contract Dose Manufacturing Market Insights Forecast to 2030
Advanced Therapy Medicinal Products Contract Development and Manufacturing Organization CDMO Services Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Biopharmaceutical CDMO Service Market Research Report 2024
Global Contract Research Development and Manufacturing Organization CRDMO Services Market Research Report 2025
Global Biopharmaceutical CDMO Market Research Report 2025
Biologics CDMO Market
Contract Research Organization CRO and CDMO for Pharmaceutical Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Biopharmaceutical and Bio CDMO Market Research Report 2024

RELATED REPORTS

Global Pharma and Healthcare Social Media Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-14Y6812
Fri Sep 12 00:00:00 UTC 2025

Add to Cart

Global Food Additives Testing Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-34O3983
Fri Sep 12 00:00:00 UTC 2025

Add to Cart

Global Gabapentin API Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-9V17601
Fri Sep 12 00:00:00 UTC 2025

Add to Cart

Global Electronic Informed Consent Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-22C17047
Fri Sep 12 00:00:00 UTC 2025

Add to Cart

Call
Buy Now
REQUEST FREE SAMPLE REPORT
Support Contacts
U.S. (TOLL FREE)
+1 (425) 388-2538
THE COMPANY
OUR PRODUCTS
CUSTOMER SUPPORT
POLICES
THE COMPANY
CUSTOMER SUPPORT
OUR PRODUCTS
POLICES
Copyright © 2018 Valuates.com. All Rights Reserved.
Sitemap - Privacy Policy - Terms & Conditions